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Background: Inhalational anesthetics potentiate nondepolarizing muscle relaxants. Cisatracurium is a recently 
introduced neuromuscular blocker in Korea. We studied the effect of inhalational anesthesia and total intravenous 
anesthesia (TIVA) on neuromuscular blockades and hemodynamic responses by cisatracurium bolus injection. 
Methods: Forty patients undergoing elective surgery were randomly divided into isoflurane and propofol-
remifentanil groups. A bolus dose of cisatracurium of 0.15 mg/kg (3 × ED95) was administered after induction and the 
onset time and clinical duration of action were recorded. The nueromuscular blockade was monitored using train-of-
four (TOF) stimulation. Hemodynamic parameters were also recorded. 
Results: Onset time was 194.0 ± 39.1 sec in the isoflurane group and 226.5 ± 62.2 sec in the propofol-remifentanil 
group. Clinical duration of action was 49.2 ± 9.0 min in the isoflurane group and 43.0 ± 9.2 min in the propofol-
remifentanil group. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) immediately before intubation 
decreased in the propofol-remifentanil group. Heart rate (HR), SBP and DBP 1 and 3 min after tracheal intubation 
increased in the isoflurane group. 
Conclusions: Onset time was similar between isoflurane and propofol-remifentanil anesthesia. Clinical duration 
of action was significantly longer in isoflurane anesthesia. SBP and DBP immediately before intubation and HR, 
SBP and DBP 1 and 3 min after tracheal intubation were significantly different between the two groups. (Korean J 
Anesthesiol 2011; 61: 297-301)
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Introduction
Cisatracurium is a new neuromuscular blocker in Korea 
with characteristic organ independent Hofmann elimination. 
Cisatracurium does not produce plasma histamine and does 
not affect HR or blood pressure [1]. Cisatracurium is also 
effective for intubation by 3 × ED95 or 4 × ED95 bolus injection. 
Cisatracurium has a duration of action of 45 min after a 0.1 mg/
kg dose and approximately 68 min after 0.2 mg/kg [2].
Inhalational anesthetics are known to affect the pharmaco-
dynamics of neuromuscular blockers [3], and enhance the effect 
of neuromuscular blockers more than intravenous anesthetics 
such as propofol [4]. Several studies have been conducted to 
evaluate the onset time and duration of action of cisatracurium 
[1,5-8]. However, there are a few studies about the onset time of 
cisatracurium with concomitant use of inhalational anesthetics 
[9].
This study was designed to compare the effect of isoflurane 
and propofol-remifentanil anesthesia on neuromuscular 
blockade (onset time, clinical duration of action) and 
hemodynamic responses by cisatracurium bolus injection (3 × 
ED95). 
Materials and Methods 
After obtaining informed written consent approved 
by the Institutional Review Board, 40 patients, American 
Society of Anesthesiologists (ASA) physical status I or II, 
undergoing elective surgery and requiring general anesthesia 
were admitted to this prospective randomized study. All 
patients had no medical history of malignant hyperthermia, 
hypersensitivity to neuromuscular blockers, alcoholism, drug 
addiction, psychiatric, neuromuscular, cardiovascular, renal, 
or hepatic impairments. Patients were excluded if they had 
recently taken drugs known to affect neuromuscular function. 
Standard monitoring including peripheral oxygen saturation, 
heart rate (HR), non-invasive blood pressure, ECG, end-tidal 
carbon dioxide concentration and body temperature. Patients 
were randomized in two groups. Isoflurane group (n = 20 
patients) received propofol 2 mg/kg for anesthetic induction. 
After loss of eyelash reflex 50% N2O in O2 and 4 Vol% (delivered 
concentration) of isoflurane were inhaled until tracheal 
intubation. After intubation anesthesia was maintained with 
50% N2O in O2 and 1-1.5 Vol% (end tidal concentration) of 
isoflurane. Propofol-remifentanil group (n = 20 patients) 
received propofol and remifentanil for anesthetic induction 
and maintenance by using effect site target concentration 
infusion (TCI, Orchestra
TM, Fresinius Vial, France). 5 μg/ml of 
propofol and 5 ng/ml of remifentanil were started with 100% 
O2 until tracheal intubation. After intubation anesthesia was 
maintained with 50% N2O in O2 and 3 μg/ml of propofol and 
1-3 ng/ml of remifentanil. After loss of eyelash reflex, both 
groups received a bolus dose of cisatracurium of 0.15 mg/
kg over 5 sec. Tracheal intubation was performed by one 
anesthesiologist when the response to TOF stimulation was 
completely ablated. Neuromuscular blockade was assessed by 
tactile response of the adductor pollicis brevis muscle to TOF 
stimulation produced by peripheral nerve stimulator (Dual 
Stim
TM, Life-Tech, USA). Evaluation of tactile responses was 
performed by the same independent anesthesiologist. Surface 
electrodes were applied over the ulnar nerve at the wrist, and 
the ulnar nerve was stimulated supramaximally with repeated 
TOF stimuli (2 Hz for 2 sec at 10-sec intervals). Tidal volume 
and respiratory rate were controlled to maintain the end-
tidal carbon dioxide concentration between 30 and 35 mmHg. 
Heating blankets and warm forced air devices were used to 
maintain esophageal temperature between 35 and 37
oC. The 
hand, where neuromuscular transmission was assessed, was 
wrapped in cotton wool to minimize heat loss. The duration 
from completion of cisatracurium injection to ablation of first 
twitch response to TOF was defined as onset time and duration 
from ablation of first twitch response to TOF to reappearance 
of third twitch response to TOF was defined as clinical duration 
of action. Hemodynamic parameters such as HR, SBP, DBP 
were measured immediately before induction, immediately 
before tracheal intubation and 1, 3, 5 and 10 min after tracheal 
intubation. 
Prior to the study, a power analysis indicated that α was set 
to 0.05, and β was set to 0.20. This power analysis required 40 
patients, with 20 patients in each group. Statistical analyses were 
performed with SPSS 12.0 for Windows (SPSS Inc, Chicago, IL, 
USA). Statistical significance was set at P < 0.05. Chi-square test 
was used for inter-group comparison of gender. Unpaired T 
test was used to compare age, height, weight and measurement 
between the two groups. Repeated measures ANOVA was used 
to compare the measurement within the same group. All data 
were presented as means ± standard deviation (SD). 
Results
There were no significant differences between the two groups 
in age, sex, height, weight, and ASA physical status (Table 1). 
Onset time was 194.0 ± 39.1 sec in the isoflurane group and 
226.5 ± 62.2 sec in the propofol-remifentanil group (P > 0.05). 
Onset time was not different between the two groups. Clinical 
duration of action was 49.2 ± 9.0 min in the isoflurane group 
and 43.0 ± 9.2 min in the propofol-remifentanil group (P < 0.05). 
The clinical duration of action was significantly longer in the 
isoflurane group (Table 2).
Hemodynamic parameters such as HR, SBP and DBP were 299 www.ekja.org
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not different between the two groups immediately before 
induction. SBP and DBP immediately before intubation 
decreased in the propofol-remifentanil group compared to the 
isoflurane group (P < 0.05). HR, SBP and DBP 1 and 3 min after 
tracheal intubation increased in the isoflurane group (P < 0.05) 
(Fig. 1).
Discussion
Cisatracurium is an intermediate acting neuromuscular 
blocker using specific metabolic processes. It is primarily 
cleared from the body by Hofmann elimination (77%) and renal 
excretion (16%) [10]. Since Hofmann elimination is an organ-
independent chemodegradative mechanism, there is little or 
no risk of the use of cisatracurium in patients with liver or renal 
disease when compared with other neuromuscular blockers.
Inhalational anesthetics potentiate neuromuscular 
blockades mainly through a postsynaptic effect [11]. Duration 
of inhalational anesthetics critically influences neuromuscular 
effects of nondepolarizing muscle relaxants. This potentiation 
depends on time and concentration [12]. Neuromuscular 
blocking effect of cisatracurium is enhanced by desflurane, 
sevoflurane and isoflurane to a similar extent [13].
In this study we assessed the neuromuscular blockade 
by using the number of tactile response to TOF stimulation. 
Kopman reported that when the fourth evoked response to 
TOF stimulation was first palpable, the mean height of first of 
four TOF twitches value was 37 ± 8.5% (standard deviation) of 
Table 1.  Demographic Data
iso group (n=20) p/r group (n=20)
Age (yr)
Weight (kg)
Height (cm)
Sex (M/F)
  47.6 ± 14.8
  62.7 ± 13.4
162.7 ± 9.8
8/12
38.5 ± 17.8
59.1 ± 10.6
160.9 ± 6.5
6/14
Values are number of patients or mean ± SD.  iso group:  isoflurane 
group, p/r group:  propofol-remifentanil group.
Table 2.  Onset Time and Duration of Action
iso group p/r group
Onset time (sec)
Duration of action (min)
194.0 ± 39.1
49.2 ± 9.0*
226.5  ± 62.2
43.0 ± 9.2
Values are  mean ± SD.  iso group:  isoflurane group, p/r group:   
propofol-remifentanil group.  *P < 0.05.
Fig. 1. Hemodynamic Results. Heart rate (A), systolic blood pressure 
(B) and diastolic blood pressure (C). iso group: isoflurane group, p/
r group: propofol-remifentanil group, BPM: beats per minute, B/
I: before intubation, P/I 1: postintabion 1 min, P/I 3: postintabion 
3 min, P/I 5: postintabion 5 min, P/I 10: postintabion 10 min. *P < 
0.05. Compared between iso group and p/r group.300 www.ekja.org
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control within a range of 20-70% [14]. Kirkegaard et al. [15] 
reported that the mechanomyographic magnitude of the first 
TOF twitch measured at reappearance of each of the four tactile 
TOF responses were 4% (1st), 12% (2nd), 24% (3rd) and 26% 
(4th). Because counting the number of tactile response to TOF 
stimulation is subjective, we assessed neuromuscular blockades 
by the same independent anesthesiologist.
Bluestein et al. [5] reported that increasing the initial dose of 
cisatracurium (from 0.1 to 0.15 and 0.2 mg/kg), decreased the 
mean time of onset (from 4.6 to 3.4 and 2.8 min, respectively) 
and increased the mean time of clinically effective duration (45 
to 55 and 61 min, respectively). Doenicke et al. [6] reported that 
when administered immediately after thiopental, cisatracurium 
had faster onset time (105 ± 41 sec in 0.15 mg/kg and 68 ± 19 sec 
in 0.25 mg/kg). 
In our study, mean onset time of 0.15 mg/kg (3 × ED95) of 
cisatracurium was 32 sec longer in the propofol-remifentanil 
group. This result was not statistically different but small 
amount of inhaled isoflurane may slightly affect the onset 
time of cisatracurium. We recommend performing tracheal 
intubation at least 3.5 min after 0.15 mg/kg (3 × ED95) of 
cisatracurium bolus injection.
Because of the relatively longer onset time of cisatracurium, 
the remifentanil dose must be reduced during induction period. 
We used a target controlled infusion of propofol-remifentanil in 
the propofol-remifentanil group, and the target of propofol was 
kept at 5 μg/ml until tracheal intubation and kept unchanged at 
3 μg/ml in each patient during the maintenance of anesthesia 
for the entire study period. The target of remifentanil was kept 
at 5 ng/ml until tracheal intubation and kept between 1-3 ng/
ml for maintaining stable blood pressure. Remifentanil was not 
known to affect the level of neuromuscular blockade [16].
Dose of cisatracurium may be selected based on the desired 
time of intubation and the anticipated length of surgery. 
Doses of 0.15 mg/kg (3 × ED95) and 0.20 mg/kg (4 × ED95) 
of cisatracurium may produce generally good or excellent 
condition of intubation (3.4 and 2.8 min) and clinically effective 
duration(55 and 61 min) respectively [17]. 
In our study, we defined the clinical duration of action 
as duration from ablation of first twitch response to TOF to 
reappearance of third twitch response to TOF. It was 49.2 ± 9.0 
min in the isoflurane group and 43.0 ± 9.2 min in the propofol-
remifentanil group. This was relatively short from the other 
studies, because clinically using tactile count to TOF does 
not match mechanomyographic or acceleromyographic TOF 
recovery [18]. 
Nitrous oxide does not affect cisatracurium demand when 
using closed-loop computerized infusion of the muscle relaxant 
with the aim of maintaining a stable 90% neuromuscular block 
[19]. However, it potentiates inhalational anesthetics rather than 
intravenous anesthetics.
Cisatracurium does not produce plasma histamine and 
has excellent cardiovascular stability [1,6]. SBP and DBP 
immediately before intubation decreased more in the propofol-
remifentanil group and HR, SBP and DBP 1 and 3 min 
after tracheal intubation increased in the isoflurane group. 
These hemodynamic differences probably resulted from the 
interaction between cisatracurium and induction agents.
We studied the effect of isoflurane and propofol-remifentanil 
anesthesia on neuromuscular blockades and hemodynamic 
responses by cisatracurium bolus injection. The onset time of 
cisatracurim was not different between the two groups because 
of the short duration of inhalation of isoflurane, but the clinical 
duration of cisatracurium bolus injection was significantly 
longer in the inhalational anesthesia group rather than the total 
intravenous anesthesia group. 
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